Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?Mohamad Abou Chakra, Michael A. O’Donnell, Vignesh T. Packiam et al.|Expert Opinion on Pharmacotherapy|2024Cited by 18
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder TumorIan M. McElree, Michael A. O’Donnell, Vignesh T. Packiam et al.|Cancers|2024Cited by 7
Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancerMohamad Abou Chakra, Michael A. O’Donnell, Ian M. McElree et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 6
The efficacy of sequential intravesical gemcitabine and docetaxel versus BCG for the treatment of European association of urology very-high risk non-muscle invasive bladder cancerMohamad Abou Chakra, Michael A. O’Donnell, Vignesh T. Packiam et al.|Urologic Oncology Seminars and Original Investigations|2024Cited by 5
Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial CarcinomaIan M. McElree, Michael A. O’Donnell, Vignesh T. Packiam et al.|Cancers|2024Cited by 5